ZB

Zura Bio Limited

ZURA·NASDAQ

$3.67

-4.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$238.63M
EPS-1.0600
P/E Ratio-3.46
Earnings Date08/13/2026

zura

Total Debt

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of Total Debt

ZURA · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A 
18.67M
-4.3%157.5%N/A
27.23M
0.1%153.7%N/A
6.31M
-1.5%40.6%N/A
1.00M
3.4%4.4%-24.4%
50.93M
-9.3%N/AN/A
441.00K
39.6%N/AN/A
3.82M
-5.0%-6.5%N/A
10.83M
-4.5%-7.2%N/A
78.00K
6.3%-25.9%N/A
2.63M
3.9%-16.5%N/A
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.67, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $3.67